Lastly, further research should be carried out to determine whether ligands acting on sex hormone receptors (AR or ER) and the GR isoforms or AhR targeting can provide preventive measures against bladder cancer as these are known modifiers of the UGT isozymes. The gene discussed is AR; the disease is urinary bladder cancer.